|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquisition
|
2021 by Mallinckrodt Pharmaceuticals
|
|
gptkbp:acquisition_year
|
gptkb:2021
|
|
gptkbp:advertising
|
targeted healthcare professionals
aggressive marketing of Oxy Contin
|
|
gptkbp:business_model
|
pharmaceutical development and marketing
|
|
gptkbp:ceo
|
gptkb:Mark_Timney
|
|
gptkbp:clinical_trial
|
conducted for Oxy Contin
|
|
gptkbp:community_impact
|
increased addiction rates
|
|
gptkbp:competitors
|
gptkb:Johnson_&_Johnson
|
|
gptkbp:conflict
|
facing bankruptcy due to lawsuits
|
|
gptkbp:controversy
|
marketing practices
|
|
gptkbp:dissolved
|
gptkb:2021
|
|
gptkbp:employees
|
approximately 1,000
|
|
gptkbp:financials
|
September 2019
|
|
gptkbp:founded
|
gptkb:1996
|
|
gptkbp:founded_in
|
gptkb:New_York_City
|
|
gptkbp:founder
|
gptkb:John_Purdue_Gray
|
|
gptkbp:grants
|
provided for pain research
|
|
gptkbp:headquarters
|
gptkb:United_States
gptkb:Stamford,_Connecticut
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Purdue Pharma Inc.
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
|
|
gptkbp:key_people
|
gptkb:Richard_A._Sackler
|
|
gptkbp:lawsuits
|
numerous lawsuits related to opioid crisis
|
|
gptkbp:legal_issue
|
opioid crisis
extensive legal defense against lawsuits
|
|
gptkbp:legal_settlement
|
$8 billion settlement in 2020
|
|
gptkbp:market_position
|
after bankruptcy restructuring.
|
|
gptkbp:market_share
|
significant share in opioid market
|
|
gptkbp:notable_products
|
gptkb:Oxy_Contin
|
|
gptkbp:parent_company
|
gptkb:Purdue_Pharma_L._P.
|
|
gptkbp:partnership
|
addiction recovery organizations
|
|
gptkbp:partnerships
|
various healthcare organizations
|
|
gptkbp:philanthropy
|
support for addiction treatment programs
|
|
gptkbp:product_line
|
analgesics
|
|
gptkbp:products
|
pain management medications
|
|
gptkbp:public_perception
|
controversial due to opioid crisis
|
|
gptkbp:public_relations
|
efforts to improve image post-controversy
|
|
gptkbp:recalls
|
none reported
|
|
gptkbp:reformed
|
post-bankruptcy restructuring
|
|
gptkbp:regulatory_compliance
|
FDA scrutiny
|
|
gptkbp:research_focus
|
pain management
|
|
gptkbp:revenue
|
$3 billion (2018)
Oxy Contin sales
|
|
gptkbp:stock_exchange
|
not publicly traded
|
|
gptkbp:subsidiary
|
gptkb:Purdue_Pharma_L._P.
|
|
gptkbp:target_market
|
pain management patients
|
|
gptkbp:type
|
private company
|
|
gptkbp:website
|
www.purduepharma.com
|
|
gptkbp:bfsParent
|
gptkb:Purdue_Pharma_L._P.
|
|
gptkbp:bfsLayer
|
7
|